Respiratory syncytial virus (RSV) represents the main cause of acute respiratory tract infections in children worldwide and is the leading cause of hospitalization in infants. RSV infection is a self-limiting condition and does not require antibiotics. However hospitalized infants with clinical bronchiolitis often receive antibiotics for fear of bacteria coinfection, especially when chest radiography is performed due to similar radiographic appearance of infiltrate and atelectasis. This may lead to unnecessary antibiotic prescription, additional cost, and increased risk of development of resistance. Despite the considerable burden of RSV bronchiolitis, to date, only symptomatic treatment is available, and there are no commercially available vaccines. The only licensed passive immunoprophylaxis is palivizumab. The high cost of this monoclonal antibody (mAb) has led to limiting its prescription only for high-risk children: infants with chronic lung disease, congenital heart disease, neuromuscular disorders, immunodeficiencies, and extreme preterm birth. Nevertheless, it has been shown that the majority of hospitalized RSV-infected children do not fully meet the criteria for immune prophylaxis. While waiting for an effective vaccine, passive immune prophylaxis in children is mandatory. There are a growing number of RSV passive immunization candidates under development intended for RSV prevention in all infants. In this review, we describe the state-of-the-art of palivizumab’s usage and summarize the clinical and preclinical trials regarding the development of mAbs with a better cost-effectiveness ratio.

Rocca A., Biagi C., Scarpini S., Dondi A., Vandini S., Pierantoni L., et al. (2021). Passive immunoprophylaxis against respiratory syncytial virus in children: Where are we now?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(7), 1-22 [10.3390/ijms22073703].

Passive immunoprophylaxis against respiratory syncytial virus in children: Where are we now?

Rocca A.
Primo
;
Biagi C.
Secondo
;
Scarpini S.
;
Dondi A.;Vandini S.;Pierantoni L.
Penultimo
;
Lanari M.
Ultimo
2021

Abstract

Respiratory syncytial virus (RSV) represents the main cause of acute respiratory tract infections in children worldwide and is the leading cause of hospitalization in infants. RSV infection is a self-limiting condition and does not require antibiotics. However hospitalized infants with clinical bronchiolitis often receive antibiotics for fear of bacteria coinfection, especially when chest radiography is performed due to similar radiographic appearance of infiltrate and atelectasis. This may lead to unnecessary antibiotic prescription, additional cost, and increased risk of development of resistance. Despite the considerable burden of RSV bronchiolitis, to date, only symptomatic treatment is available, and there are no commercially available vaccines. The only licensed passive immunoprophylaxis is palivizumab. The high cost of this monoclonal antibody (mAb) has led to limiting its prescription only for high-risk children: infants with chronic lung disease, congenital heart disease, neuromuscular disorders, immunodeficiencies, and extreme preterm birth. Nevertheless, it has been shown that the majority of hospitalized RSV-infected children do not fully meet the criteria for immune prophylaxis. While waiting for an effective vaccine, passive immune prophylaxis in children is mandatory. There are a growing number of RSV passive immunization candidates under development intended for RSV prevention in all infants. In this review, we describe the state-of-the-art of palivizumab’s usage and summarize the clinical and preclinical trials regarding the development of mAbs with a better cost-effectiveness ratio.
2021
Rocca A., Biagi C., Scarpini S., Dondi A., Vandini S., Pierantoni L., et al. (2021). Passive immunoprophylaxis against respiratory syncytial virus in children: Where are we now?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(7), 1-22 [10.3390/ijms22073703].
Rocca A.; Biagi C.; Scarpini S.; Dondi A.; Vandini S.; Pierantoni L.; Lanari M.
File in questo prodotto:
File Dimensione Formato  
ijms-22-03703 (1).pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 618.01 kB
Formato Adobe PDF
618.01 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/851787
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 12
social impact